Warrant Exercise Price Halved to $2.50 Post-Split, Increasing Dilution Risk

summarizeSummary

Sunshine Biopharma's definitive filing reveals a 50% reduction in Series C Warrant exercise price to $2.50 post-reverse split, making them nearly exercisable and increasing future dilution.

check_boxKey Events

• Warrant Exercise Price Reduced

  The exercise price of Series C Warrants will be reduced from $5.00 to $2.50 per share, effective 20 days after the mailing of this statement, due to a provision triggered by the 1-for-10 reverse stock split.

• Increased Dilution Potential

  The 50% reduction in the warrant exercise price, bringing it close to the current stock price of $2.43, significantly increases the likelihood of warrant exercise and subsequent dilution for existing shareholders.

• Shareholder Approval Confirmed

  The company's CEO, Dr. Steve N. Slilaty, holding 86.0% of voting power, approved the warrant stockholder approval provisions by written consent on May 28, 2026.

• Follows Recent Dilutive Offering

  This adjustment relates to Series C Warrants issued in a $6.0 million public offering that closed on May 19, 2026, which was already noted for its highly dilutive nature.

auto_awesomeAnalysis

This definitive information statement confirms shareholder approval for warrant provisions, crucially detailing that the Series C Warrants' exercise price will be reduced from $5.00 to $2.50 following the recent 1-for-10 reverse stock split. This 50% reduction, effective 20 days after mailing, makes the warrants nearly at-the-money with the current stock price of $2.43, significantly increasing the likelihood of exercise and future dilution for existing shareholders. This comes after a highly dilutive $6 million offering and worsening financial health.